Vaccinia Immune Globulin in Treating or Preventing Vaccinal Infection
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to follow responses to treatment with vaccinia immune globulin
(VIG) for safety and clinical benefit [during HIV vaccine research].
VIG is purified from human blood and used to treat serious infections of the vaccinia
(smallpox vaccine) virus or similar viruses. It is the only treatment available for those
viruses. The only available supply of VIG has developed a discoloration over time and
therefore is considered an investigational new drug by the FDA. This study will allow it to
be used for intramuscular injection in a controlled setting for people who may need it
[during HIV vaccine research].
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)